A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
| Status: | Archived |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2009 |
| End Date: | May 2015 |
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is
effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who
have not received any prior systemic therapy except surgery or locoregional therapy.
Disease status and disease progression will be assessed every 8 weeks. Subjects will remain
on treatment until: progressive disease by RECIST criteria; death or loss to follow-up; or
withdrawal of informed consent.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials